학술논문

SRF617, a potent enzymatic inhibitor of CD39, demonstrates single-agent activity and cooperates with various cancer therapies in both solid tumor and hematologic malignancies
Document Type
Journal
Source
CANCER RESEARCH; AUG 2020, 80 16, 2p. Supplement: S
Subject
Language
English
ISSN
15387445